Ads
related to: glaxosmithkline pharmaceuticals
Search results
These Inhalers No Longer Cost More Than $35 Per Month
Verywell Health via Yahoo News· 2 days agoChanges were made in response to pressure from lawmakers. Amidst untenable drug prices, there's...
Experts say Medicaid rebate change is behind inhaler price cuts | Texarkana Gazette
Texarkana Gazette· 1 day agoThree of the four major inhaler manufacturers have announced plans to cap patient copays for all...
Healthy Returns: Drugmakers are capping inhaler prices at $35 in a win for some patients
CNBC· 2 days agoThree of the world's largest inhaler makers have agreed to cap the out-of-pocket price of their...
Amivantamab Offers Post-Progression Benefit in EGFRm NSCLC
Medscape· 7 hours agoEven if patients with EGFR-mutated lung cancer progress on amivantamab plus chemotherapy, there is a...
UK biopharma company IntraBio moves HQ to Austin, raises $40M - Austin Business Journal
The Business Journals· 2 days agoA U.K.-based biopharmaceutical company that just raised a new round of funding moved its corporate...
No. 7: Doug Langa
NJBIZ· 3 days agoLanga – who previously held positions at GlaxoSmithKline and Johnson & Johnson – has said he believes a “significant portion” of Novo Nordisk’s growth...
Senators Have Pushed Big Pharma to Cap Inhaler Prices at $35–Bringing Relief to American Families
GoodNewsNetwork· 3 days agoLess than three months after U.S. Senator Tammy Baldwin and her colleagues launched an investigation...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 2 days agoNEWARK, Del, March 26, 2024 (GLOBE NEWSWIRE) -- As per Future Market Insights (FMI), global respiratory biologics market are estimated to be worth US$ 8,154.6 million in 2024. The market is expected to reach US$ 42,319.9 million, expanding at
32 Countries with the Highest Rates of Diabetes
Insider Monkey via Yahoo Finance· 2 days agoIn this article, we will be taking a look at the 32 countries with the highest rates of diabetes. If you do not want to learn about the global diabetes...
CT-based Boehringer Ingelheim to cap out-of-pocket inhaler costs at $35
Stamford Advocate· 6 days agoSenate committee launched an investigation of the Ridgefield-based company and several other ...
Ads
related to: glaxosmithkline pharmaceuticals